GENOR BIOPHARMA DL-00002 (67N0) — Cash Flow-to-Debt Ratio
GENOR BIOPHARMA DL-00002 (67N0) has a Cash Flow-to-Debt Ratio of -0.88x as of December 2024, meaning its operating cash flow of €-121.98 Million could theoretically repay -1% of its total liabilities (€138.05 Million) in one year. See working capital to net assets of GENOR BIOPHARMA DL-00002 to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
GENOR BIOPHARMA DL-00002 Cash Flow-to-Debt Ratio (2021–2024)
Historical debt coverage capacity for GENOR BIOPHARMA DL-00002 across 4 annual periods. Also explore 67N0 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for GENOR BIOPHARMA DL-00002 (2021–2024)
Year-by-year debt coverage analysis for GENOR BIOPHARMA DL-00002. For market capitalisation and broader financial context, see how much is GENOR BIOPHARMA DL-00002 worth.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.88x | €-121.98 Million | €138.05 Million | ▲ +46.8% |
| 2023 | -1.66x | €-425.12 Million | €256.18 Million | ▲ +11.0% |
| 2022 | -1.86x | €-577.61 Million | €309.87 Million | ▼ -10.5% |
| 2021 | -1.69x | €-623.74 Million | €369.73 Million | — |